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Abstract: Suppression of insulin-like growth factor 1 (IGF-1) and leptin secondary to low energy 
availability (LEA) may contribute to adverse effects on bone health. Whether a high-protein diet 
attenuates these effects has not been tested. Seven men completed three five-day conditions opera-
tionally defined as LEA (15 kcal kg fat-free mass (FFM)-1 day-1) with low protein (LEA-LP; 0.8 g 
protein·kg body weight (BW)-1), LEA with high protein (LEA-HP; 1.7 g protein·kg BW-1) and control 
(CON; 40 kcal·kg FFM-1·day-1, 1.7 g protein·kg BW-1). In all conditions, participants expended 15 
kcal·kg FFM-1·day-1 during supervised cycling sessions. Serum samples were analyzed for markers 
of bone turnover, IGF-1 and leptin. The decrease in leptin during LEA-LP (-65.6 ± 4.3%) and LEA-
HP (-54.3 ± 16.7%) was greater than during CON (-25.4 ± 11.4%; p = 0.02). Decreases in P1NP (p = 
0.04) and increases in CTX-I (p = 0.04) were greater in LEA than in CON, suggesting that LEA shifted 
bone turnover in favour of bone resorption. No differences were found between LEA-LP and LEA-
HP. Thus, five days of LEA disrupted bone turnover, but these changes were not attenuated by a 
high-protein diet. 
Keywords: caloric restriction; aerobic exercise; energy deficit 
 
1. Introduction 
Energy availability represents the dietary energy remaining for physiological func-
tions following the deduction of exercise expenditure [1]. At a threshold of 30 kcal · kg 
fat-free mass (FFM)-1·day-1 [2], an abundance of hormonal disturbances characterizing low 
energy availability occurs [1]. In addition to the well-documented suppression of sex hor-
mones [3], key metabolic hormones involved in the regulation of bone metabolism, such 
as insulin-like growth factor 1 (IGF-1) and leptin, are suppressed by low energy availabil-
ity [2]. Reductions in IGF-1 secondary to low energy availability have been associated 
with bone loss [4] and reduced bone mineral density [5] while low leptin levels have been 
linked to a higher risk of fracture [6]. 
By definition, energy availability can be lowered through a reduction in energy in-
take, an increase in exercise energy expenditure or a combination of both. This places in-
dividuals with large exercise energy expenditures, such as endurance athletes, at a greater 
risk of experiencing low energy availability compared to those primarily engaging in 
training modalities with a lower exercise energy expenditure, such as resistance training 
[7]. Furthermore, individuals practicing non-weight-bearing exercise modalities have ad-
ditional risk for adverse bone health outcomes as non-weight-bearing exercise modalities 
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show less benefit to skeletal health than their weight-bearing counterparts [8]. At the in-
tersection of a high exercise energy expenditure and practice of non-weight-bearing exer-
cise are athletes such as cyclists who, indeed, display an increased risk for low energy 
availability [9] and a high prevalence of low bone mineral density [10] likely originating 
from this combination of risk factors. Thus, for these and other athletes at risk for experi-
encing periods of low energy availability, additional measures to mitigate the harmful 
effects of low energy availability on bone health are needed. 
One strategy with underexplored potential is that of dietary protein. During periods 
of low energy availability, protein requirements, particularly for athletes, are elevated 
[11]. Increased dietary protein preserves lean mass, which is positively associated with 
bone mineral density [12]. Indeed, a high-protein diet has been shown to preserve lean 
mass and bone mineral density similar to an energy balance control during a six-month 
weight loss intervention [13]. Maintenance of lean mass and bone mineral density during 
periods of low energy availability in athletes may improve performance capacity and re-
duced risk for future injury, or even osteoporosis later in life [14,15]. Mechanistically, high 
protein intakes may exert these protective effects by attenuating reductions in IGF-1 char-
acteristic of low energy availability exposure. This hypothesis comes from the observation 
that low protein intakes have been shown to suppress IGF-1 even without the presence of 
energy restriction [16].  
Therefore, the purpose of our pilot study was to first confirm the effects of low energy 
availability induced by a combination of dietary energy restriction and exercise energy 
expenditure on hormones such as IGF-1 and leptin and downstream markers of bone turn-
over using a non-loading form of aerobic exercise, namely cycling. Previous research ex-
amining the impact of low energy availability induced via exercise energy expenditure on 
bone markers has been limited to the use of weight-bearing running exercise [17,18]. Ad-
ditionally, we wanted to explore whether increased dietary protein preserves upstream 
signals from IGF-1 or leptin and blunts the bone turnover marker response during short-
term low energy availability. While IGF-1 has been shown to respond to protein restriction 
independent of energy restriction [16], leptin is tightly linked to energy availability and 
likely will not respond to increased protein intake without a change in energy availability. 
Thus, we hypothesize that low energy availability will decrease circulating IGF-1 and lep-
tin as well as increase bone resorption and decrease bone formation. We anticipate that a 
high-protein diet will attenuate the effects of low energy availability on IGF-1 and bone 
turnover markers, but not leptin.  
2. Materials and Methods 
2.1. Study Design 
The present randomized, single-blind repeated measures crossover pilot study con-
sisted of three five-day conditions (Table 1), a sufficient duration for detecting changes in 
metabolic hormones and markers of bone turnover in response to low energy availability 
[18]. Two conditions restricted energy intake to 30 kcal·kg fat-free mass (FFM)-1·day-1 
(LEA). In one LEA condition (LEA low protein; LEA-LP), participants consumed 0.8 g·kg 
body weight (BW)-1·day-1 protein in accordance with the recommended daily allowance. 
The other LEA condition (LEA high protein; LEA-HP) provided participants 1.7 g·kg BW-
1·day-1 protein, an amount reflecting the upper limit of protein recommended for athletes 
by the American College of Sports Medicine [19] which has been shown to preserve lean 
mass during energy restriction [20]. Participants also underwent a condition which pro-
vided them 55 kcal·kg FFM-1·day-1 and 1.7 g·kg BW-1·day-1 protein, operationally defined 
as the control condition (CON). Participants expended 15 kcal·kg FFM-1 ·day-1 in super-
vised exercise sessions during all conditions. This resulted in a net energy availability after 
daily exercise of 15 kcal·kg FFM-1·day-1 in the LEA conditions and 40 kcal·kg FFM-1·day-1 
in the CON condition. These levels of energy availability have induced significant weight 
loss and maintained weight, respectively, in a similar intervention [21]. Participants were 
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randomly assigned to one of six condition sequences by a random number generator and 
completed a washout period of at least two weeks between conditions during which they 
continued habitual exercise and dietary practices. This duration of washout period is 
slightly longer than what has previously been used (10 days) to recover body weight and 
metabolic hormones following short-term exposure to an LEA of 15 kcal·kg FFM-1·day-1 
[21]. The study was approved by the University of Nebraska—Lincoln’s Institutional Re-
view Board (IRB#15895; Approved 17 March 2016) and registered at www.clinicaltri-
als.gov (NCT02945410). 
Table 1. Energy and protein characteristics of the three conditions 
Condition LEA-LP LEA-HP CON 
Energy Intake1 30 30 55 
Exercise Energy Expenditure1 15 15 15 
Energy Availability1 15 15 40 
Protein Intake2 0.8 1.7 1.7 
Abbreviations: LEA-LP, low energy availability with low protein; LEA-HP, low energy availability 
with high protein, CON, control. 1 units: kcal·kg FFM-1·day-1; 2 units: g·kg body weight-1 
2.2. Participants 
We conducted the pilot study between September 1, 2016 and January 15, 2018. Par-
ticipants were recruited from campus and other local recreation sites via flyers, emails to 
campus sports clubs and social media posts. Participants were nonsmokers between 19 
and 30 years old with a normal body fat percentage (<20%) as measured by skinfold meas-
urement (CE 0120, Harpenden, UK) and completed ≥ 4 hours of purposeful aerobic exer-
cise per week for six months prior to beginning the study. We selected young participants 
for the study to ensure participants could recover quickly from the high physical demands 
of the study while lean participants lose greater amounts of lean mass during weight loss 
[22], which maximized effect sizes. Recruiting trained participants reduced training ef-
fects of the interventions and ensured participants would be able to complete and recover 
from daily exercise sessions. Compliance to these inclusion criteria was confirmed during 
an initial screening visit to the laboratory after the informed consent was signed.  
2.3. Preliminary Testing 
During preliminary testing, participants had their height and weight taken by an 
electronic stadiometer (222 and 769, SECA, Germany) and their body composition as-
sessed by bioimpedance analysis (Quadscan 4000, BodyStat, UK). Participants also com-
pleted a graded exercise test on a cycle ergometer (LC6, Monark HB, Sweden) to assess 
peak oxygen consumption (VO2peak). Participants began cycling at 60 W for 3 minutes 
and the intensity was increased by 35 W every 3 minutes until volitional exhaustion, 
which required at least 3 of the following: (1) cadence < 60 rpm, (2) respiratory exchange 
ratio ≥ 1.1, (3) heart rate ≥ 90% of age-predicted maximum (220-age), (4) plateau in oxygen 
uptake despite increasing workload, (5) rating of perceived exertion ≥ 19. Respiratory data 
were analyzed by a metabolic cart (QUARK CPET, COSMED, USA) and used to deter-
mine the intensity corresponding to 60% VO2peak.  
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2.4. Diet Preparation 
Participants were provided all food consumed during each five-day condition. Diets 
consisted of an individually tailored combination of clinical products (Ensure Plus; 4.57 g 
protein · 100 kcal-1 and Ensure High Protein; 10 g protein · 100 kcal-1, both Abbott Nutri-
tion, USA) and maltodextrin (Tate and Lyle, UK). The LEA-LP diet consisted of Ensure 
Plus providing 0.8 g·kg BW-1 protein and maltodextrin added to achieve a caloric intake 
of 30 kcal·kg FFM-1·day-1. In the remaining conditions, maltodextrin consumption was 
matched with LEA-LP and the required amounts of the two clinical products were calcu-
lated to obtain 1.7 g·kg BW-1 ·day-1 and either 30 kcal·kg FFM-1·day-1 (LEA-HP) or 55 kcal·kg 
FFM-1·day-1 (CON). Participants consumed their maltodextrin during daily exercise bouts 
dissolved in 800 mL water·hour-1 exercise with 1.2 g sodium chloride·L-1 to attenuate de-
hydration and enhance palatability [23]. We supplied a wholly liquid diet from products 
used in previous interventions [2] to accurately measure intake and blind participants by 
matching dietary volume between conditions via dilutions with water. Participants were 
required to consume their food in ≥3 meals spread throughout the day and each partici-
pant consumed the same number of meals every day throughout the entire study. During 
the conditions, participants were permitted to consume non-caloric beverages, but were 
asked to record consumption of these products. 
2.5. Supplementation 
To mitigate differences in calcium and vitamin D consumption, we supplemented 
participant intake of these micronutrients throughout the entire study, including washout 
periods. Calcium and vitamin D provided during each condition were supplemented to 
make up the difference from the largest amount provided during the study. Supplemen-
tation of calcium during washout periods was calculated as the difference between the 
amount provided within conditions and habitual calcium intake determined using the 
Brief Calcium Assessment Tool [24]. Vitamin D was supplemented at the maximal amount 
provided by any condition. Participants were provided all supplements in pill boxes spac-
ing them into 1–3 doses per day depending on number of supplements consumed. 
2.6. Daily Exercise Prescription 
Daily aerobic exercise sessions on the cycle ergometer were calibrated to expend 15 
kcal· kg FFM-1·day-1 at the power output corresponding to 60% of VO2peak achieved dur-
ing the preliminary graded exercise test. Duration of the daily exercise sessions was cal-
culated by dividing the target energy expenditure of the exercise session by the rate of 
energy expenditure at the determined power output. Additional exercise and intense 
physical activity were prohibited. Compliance was measured via a waist-worn accelerom-
eter (ActiLife G3TX+, ActiGraph, USA).  
2.7. Measurements and Assessments 
All measurements were performed in an identical order before (pre) and after (post) 
each five-day condition. Participants reported to the laboratory between 0700 and 0800 
following an overnight fast of at least 12 hours. Body weight and composition were meas-
ured as reported for preliminary assessments. Then a blood sample was collected from 
the antecubital vein. Serum aliquots were stored at -80°C until analysis. 
Commercially available assays were used to measure serum concentrations of IGF-1 
[R&D Systems, USA], insulin-like growth factor binding protein-3 (IGFBP-3) [R&D Sys-
tems, USA], Leptin [Mediagnost, Germany], CTX-I [ABClonal, USA], P1NP [Cloud Clone, 
USA] and sclerostin [Biomedica, USA]. In-house intraassay variabilities for each assay 
were 3.24% (IGF-1, sensitivity: 0.056 ng/mL), 3.37% (IGFBP-3, sensitivity: 0.14 ng/mL), 
1.92% (Leptin, sensitivity: 0.25 μg/L), 7.66% (CTX-I, sensitivity: 0.1 ng/mL), 6.69% (P1NP, 
sensitivity: 17.71 pg/mL) and 7.30% (sclerostin, sensitivity: 3.17 pmol/L). The IGF-1: 
IGFBP-3 Ratio (IGFR) was calculated by multiplying the ng/mL concentrations of IGF-1 
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and IGFBP-3 provided from the assay by 0.13 and 0.036, respectively, to obtain molar con-
centrations and dividing the molar concentration of IGF-1 by the molar concentration of 
IGFBP-3 [25].  
2.8. Statistical Analyses 
Changes from pre- to post-condition were expressed in the original units for body 
composition outcomes and IGFR and percentage changes for markers of bone turnover 
(P1NP, CTX-I and sclerostin), IGF-1 and leptin. Prior to analysis, all data were examined 
for outliers, defined as values greater than three standard deviations away from the mean, 
and assessed for normality using the Shapiro–Wilk test. Following the removal of one 
outlier in the IGF-1 data, all data were determined to be normally distributed. All out-
comes were first analyzed for the effect of LEA by ANOVA. Post hoc, one-sided paired t-
tests were then performed on hypothesized differences between LEA-LP and LEA-HP. 
Sample size was determined based on literature reporting changes in IGF-1 following the 
reduction in energy availability to 10 kcal·kg FFM-1·day-1 for five days [2]. From this data, 
we anticipated an effect size of 1.1 and a sample size of n = 7 was deemed sufficient to 
detect differences with a power of 0.80. All statistical analysis was performed using R (R 
Core Team, Version 3.6). Unless otherwise stated, all data in text and figures are reported 
as mean ± standard error of the mean (SEM). We defined statistical significance as p < 0.05. 
3. Results 
3.1 Participant Characteristics and Compliance 
Of the 15 participants allocated to an intervention, 10 participants completed at least 
one condition and seven participants finished all three conditions (Supplementary Figure 
S1). At baseline, the seven completers were 23.9 ± 1.5 years of age, weighed 86.9 ± 2.9 kg 
with 13.4 ± 2.0% body fat and had an average VO2peak of 42.6 ± 2.4 mL·kg-1 ·min-1. Com-
pleters did not differ from participants allocated to an intervention but unable to complete 
all conditions on any of the aforementioned variables (all t > 1.28, p > 0.20).  
During each condition, completers exercised at an intensity of 124 ± 12 Watts for 115 
± 10 minutes to expend 15 kcal·kg FFM-1·day-1. All participants attended 100% of their 
prescribed exercise sessions in each condition. Participants exchanged their empty bever-
age containers from the previous day for their next days’ meals at each exercise session in 
addition to completing a dietary intake log of the beverages for each condition. Based on 
these procedures, dietary compliance was 100%.  
3.2 Body Weight and Composition 
Completers lost similar amounts of body weight during LEA-HP (-2.27 ± 0.50 kg) and 
LEA-LP (-2.13 ± 0.30 kg) but not CON (-0.01 ± 0.33 kg; F = 19.05, p = 0.002). Due to technical 
difficulties, complete body composition data were only available for five participants (Fig-
ure 1). These five completers lost more fat mass (FM) (-1.14 ± 0.23 kg and -0.92 ± 0.18 kg 
vs. -0.10 ± 0.40 kg; F = 8.76, p = 0.02) and dry lean mass (DLM) (-0.36 ± 0.07 kg and -0.33 ± 
0.07 kg vs. -0.06 ± 0.05 kg; F = 10.44, p = 0.01) in LEA conditions compared to CON. Losses 
of FM (mean difference = -0.22, t = -1.20, p = 0.15) and DLM (mean difference = -0.04, t = -
0.52, p = 0.69) were not significantly different between LEA-HP and LEA-LP.  




Figure 1. Changes in body composition by condition. Abbreviations: FM, fat mass; TBW, total 
body water; DLM, dry lean mass; CON, control; LEA-HP, low energy availability with high pro-
tein; LEA-LP, low energy availability with low protein. * indicates p < 0.05 LEA vs. CON for each 
compartment. 
3.3 Leptin, IGF-1 and IGFR 
Pre- and post-condition measurements for all hormonal outcomes are reported in Ta-
ble 2. Decreases in leptin were greater during LEA-HP (-54.3 ± 16.7%) and LEA-LP (-65.6 
± 4.3%) conditions than during CON (-25.4 ± 11.4%; F = 7.50, p = 0.02). The differences in 
changes in IGF-1 between LEA (HP: -8.1 ± 7.3%; LP -11.8 ± 5.4%) and CON (2.9 ± 9.4%; F 
= 2.42, p = 0.14) did not achieve statistical significance (Figure 2). Differences in IGFR 
changes followed the same pattern as IGF-1 (F = 2.37, p = 0.15). Due to the lack of difference 
between LEA and CON conditions, the difference between LEA-HP and LEA-LP was not 
tested.  
Table 2. Biomarker responses to each condition 
Hormone Condition Pre Post % Change LEA vs. CON p value 
P1NP  
(μg/L) 
LEA-LP 90.9 ± 11.7 77.9 ± 12.2 -14.9 ± 6.5% 
0.04 LEA-HP 85.4 ± 11.8 61.7 ± 7.6 -24.8 ± 6.2% 
CON 85.0 ± 8.2 80.8 ± 8.7 -4.4 ± 5.5% 
CTX-I 
(ng/mL) 
LEA-LP 1.30 ± 0.16 1.39 ± 0.19 6.9 ± 6.2% 
0.04 LEA-HP 1.22 ± 0.10 1.23 ± 0.10 0.2 ± 2.1% 
CON 1.47 ± 0.19 1.32 ± 0.14 -8.3 ± 3.9% 
Sclerostin 
(pmol/L) 
LEA-LP 31.4 ± 2.9 36.4 ± 4.7 15.0 ± 8.4% 
0.81 LEA-HP 30.4 ± 3.6 30.8 ± 3.5 3.2 ± 6.9% 
CON 28.6 ± 5.4 30.3 ± 5.6 6.6 ± 9.5% 
Leptin  
(μg/L) 
LEA-LP 3.28 ± 1.77 1.44 ± 0.89 -65.5 ± 4.4% 
0.02 LEA-HP 2.50 ± 1.21 1.23 ± 0.75 -54.3 ± 16.7% 
CON 3.03 ± 1.24 2.57 ± 1.51 -25.4 ± 11.4% 
IGF-1 
(ng/mL) 
LEA-LP 228 ± 30 200 ± 27 -11.8 ± 5.4% 
0.14 LEA-HP 202 ± 29 180 ± 21 -8.1 ± 7.3% 
CON 225 ± 33 221 ± 20 2.9 ± 9.4% 
IGFBP-3 
(ng/mL) 
LEA-LP 2418 ± 131 2281 ± 111 -5.2 ± 3.6% 
0.61 LEA-HP 2282 ± 186 2311 ± 80 4.1 ± 7.3% 
CON 2612 ± 132 2502 ± 117 -3.9 ± 2.7% 
IGFR  LEA-LP 0.34 ± 0.05 0.32 ± 0.04 - 0.15 
Nutrients 2021, 13, 802 7 of 12 
 
 
(no units) LEA-HP 0.34 ± 0.07 0.28 ± 0.04 - 
CON 0.32 ± 0.06 0.32 ± 0.04 - 
P1NP, CTX-I, Sclerostin, Leptin (n = 7); IGF-1, IGFBP-3, IGFR (n = 6). Abbreviations: P1NP, procol-
lagen type I N-terminal propeptide; CTX-I, type I collagen cross-linked C-telopeptide; IGF1, insu-
lin-like growth factor-1; IGFBP3, insulin-like growth factor binding protein 3; IGFR, insulin-like 
growth factor ratio; LEA-LP, low energy availability with low protein; LEA-HP, low energy avail-
ability with high protein; CON, control. 
 
Figure 2. Changes in IGFR and its components by condition. Abbreviations: CON, control; LEA-
LP, low energy availability with low protein; LEA-HP, low energy availability with high protein; 
M, molar concentration; IGF1, insulin-like growth factor-1; IGFBP3, insulin-like growth factor 
binding protein 3; IGFR, insulin-like growth factor ratio. 
3.4 Markers of Bone Turnover 
As shown in Figure 3, P1NP decreased to a greater extent during LEA-HP (-24.8 ± 
6.2%) and LEA-LP (-14.9 ± 6.5%) conditions than during CON (-4.4 ± 5.5%; F = 4.95, p = 
0.04). CTX-I increased to a greater extent during LEA-HP (0.2 ± 2.1%) and LEA-LP (6.9 ± 
6.2%) conditions than during CON (-8.3 ± 3.9%; F = 5.00, p = 0.04). However, changes in 
Sclerostin were not different between LEA and CON (LEA-HP, 3.2 ± 6.9%; LEA-LP, 15.0 ± 
8.4%; CON, 6.6 ± 9.5%; F = 0.06, p = 0.81). None of the changes in the turnover markers 
above achieved statistically significant differences between LEA-HP and LEA-LP (P1NP, 
t = -1.01, p = 0.82; CTX-I, t = -0.91, p = 0.16; sclerostin, t = -0.94, p = 0.19, respectively). 




Figure 3. Changes in markers of bone turnover by condition. Abbreviations: CTX-I, type I collagen 
cross-linked C-telopeptide; P1NP, procollagen type I N-terminal propeptide; CON, control; LEA-
LP, low energy availability with low protein; LEA-HP, low energy availability with high protein. * 
indicates p < 0.05 LEA vs. CON 
4. Discussion 
The present intervention examined the effects of acute low energy availability expo-
sure on upstream metabolic hormones leptin and IGF-1 as well as downstream markers 
of bone turnover in men performing daily non-weight-bearing exercise. To our 
knowledge, the present pilot study is the first controlled low energy availability interven-
tion to explore the ability of a high-protein diet to attenuate the effects of low energy avail-
ability on bone turnover. Our results show five days of low energy availability achieved 
through dietary restriction and daily cycling exercise decreased circulating levels of lep-
tin, but not IGF-1, and reduced bone formation and increased bone resorption. However, 
the high-protein diet showed a limited ability to blunt these responses.  
In agreement with our hypotheses, leptin declined in response to low energy availa-
bility. This supports reductions previously observed in lean men [21], sedentary women 
[2] and a pooled analysis of active men and women [18] in response to low energy avail-
ability exposure. Positive associations between leptin and bone mineral density have been 
widely reported and a growing body of literature supports both direct and indirect mech-
anisms of action responsible for this observation [26]. Whether reductions in leptin per se 
are responsible for the shift in bone turnover to favour bone resorption during low energy 
availability has not been examined. However, we also speculate that leptin makes a poor 
target for intervention given how robustly it responds to low energy availability, regard-
less how energy availability is reduced. 
In contrast, we were unable to observe a significant effect of low energy availability 
on IGF-1 or IGFR. Seminal work on the threshold for disruption of hormones showed that 
IGF-1 decreased in a dose-dependent fashion across 30, 20 and 10 kcal · kg FFM-1 · day-1 in 
sedentary women [2]. This finding has been supported in a pooled group of men and 
women by the work of Papageorgiou et al. [18]. However, previous work in lean, trained 
men similar to our own population did not observe significant changes in IGF-1 at an 
energy availability of 15 kcal·kg FFM-1·day-1 [21]. The less consistent findings in men com-
pared to women suggest that IGF-1 may not respond as robustly to low energy availability 
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in men as in women. Potential explanations for this observation include increased periph-
eral synthesis of IGF-1 by skeletal muscle [27] due to a greater appendicular lean mass in 
men or a divergent relationship between IGF-1 and estrogen vs. testosterone [28].  
Furthermore, a high-protein diet did not beneficially impact the IGF-1 response to 
low energy availability. We previously showed a single bolus of 30 g whey protein given 
post-resistance exercise was unable to protect against the decline in IGF-1 observed dur-
ing low energy availability [29]. We speculated that a more consistent delivery of in-
creased dietary protein (e.g., a high-protein diet) was needed to observe effects of protein 
on IGF-1. While we were unable to observe such effects in the present study, a one-year 
weight loss intervention in postmenopausal women did find that a high-protein diet ele-
vated both IGF-1 and IGFBP-3 in addition to improving bone mineral density at several 
sites [30]. We speculate the relationships between dietary protein, IGF-1 and bone health 
may be mediated by the preservation of lean mass—which is associated with bone mineral 
density [12]—and require a sufficient duration for differences in lean mass preservation 
to appear in order to manifest. However, the aforementioned one-year intervention did 
not observe any differences in lean mass changes between their protein intakes [30]. Thus, 
it remains to be determined what role dietary protein plays in moderating changes in IGF-
1 and whether this causally influences bone health.  
Low energy availability significantly impaired bone formation, indicated by circulat-
ing P1NP, and elevated bone resorption, indicated by circulating CTX-I. P1NP has previ-
ously been shown to decrease in response to low energy availability induced by daily 
running exercise [17,18]. This agreement between our results suggests that our choice of 
a non-weight-bearing exercise modality likely did not contribute to these findings. Previ-
ous research has reported a strong correlation (r = 0.97) between P1NP and IGF-1 [17]. In 
the present study, our pre- and post-condition values were only moderately correlated (r 
= 0.66). However, it is promising that we observed a similar P1NP response to LEA in the 
present study (~15–25%) to that reported in previous research by Zanker and Swaine 
(15%) [17] and Ihle and Loucks (20–25%) [4]. Though we observed statistically significant 
differences for CTX-I between LEA and CON, the magnitude of these changes is below 
reported ranges for intraindividual variability (~10%) [30]. However, our strict control 
over diet, exercise, physical activity as well as calcium and Vitamin D likely reduced the 
potential intraindividual variability in the present study.  
In the present intervention, consumption of a high-protein diet did not appear to 
protect against reduced P1NP but showed signs of a protective effect on CTX-I we were 
not adequately powered to detect. Our observations match that of longer duration inter-
ventions which found no effect of a high-protein diet on P1NP [31] and a protective effect 
on CTX-I [32]. This combination of findings is interesting given that the effects of protein 
on other tissues, such as lean mass, are often mediated by anabolic and not anti-catabolic 
effects.  
Unlike P1NP and CTX-I, sclerostin did not appear to be impacted by low energy 
availability in the present intervention. Previously, we reported an increase in sclerostin 
following just two days of low energy availability and inactivity which was attenuated by 
performing a bout of resistance exercise on the third day [29]. The absence of a significant 
increase in the present study suggests that even non-weight-bearing aerobic exercise, 
when performed daily, may be sufficient to prevent significant elevations in sclerostin 
during short periods of low energy availability. This is a surprising finding given that 
sclerostin is produced in response to mechanical unloading and suppressed by mechani-
cal loading [33]. However, sclerostin has previously been shown to respond to both 
weight-bearing and non-weight-bearing exercise stimuli when both P1NP and CTX-I did 
not [34]. Thus, it appears that sclerostin may respond more robustly to the exercise stim-
ulus, even during low energy availability, than the standard markers, P1NP and CTX-I, 
though additional data are needed to support this hypothesis.  
Our intervention is one of a limited number of diet and exercise interventions de-
signed to prospectively study the effects of low energy availability exposure. We strictly 
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controlled energy availability through supplying participants with all meals and super-
vising exercise bouts each day of the intervention. All of this was done to study the effects 
in men alone. We chose this study population due to the scarcity of research on the effects 
of low energy availability in men and to help clarify some of the less consistent findings 
in men compared to women. Albeit small, the sample size (n = 7) is similar to previous 
controlled LEA experiments (n = 6–11) [2,17,18,21,29] and our use of a crossover design 
adequately powered the pilot study to detect changes similar to those seen in previous 
studies as a result of LEA [2]. Additional research, particularly in larger studies, is still 
needed to investigate the effects of high-protein diets during LEA. Nonetheless, the pre-
sent study supports existing low energy availability literature by reinforcing the effects of 
low energy availability on markers of bone turnover and introducing the potential of high-
protein diets to augment the effects of exercise in the context of low energy availability.  
5. Conclusions 
In the present pilot study, low energy availability achieved through a combination of 
energy restriction and daily cycling exercise reduced circulating levels of leptin, but not 
IGF-1, in men. Despite this, the combined reduction in bone formation and elevation in 
bone resorption still signaled a shift in bone turnover favoring resorption. Consuming a 
high-protein diet during low energy availability did not significantly attenuate these ef-
fects. Additional research is needed to further explore the differential responses of IGF-1 
to low energy availability between men and women and further investigate the potential 
of high-protein diets as a strategy to attenuate these deleterious effects.  
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